Tempest Therapeutics’ (TPST) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research report released on Wednesday,Benzinga reports. They currently have a $47.00 price target on the stock.

Tempest Therapeutics Price Performance

TPST stock opened at $0.97 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.17 and a quick ratio of 2.17. Tempest Therapeutics has a 1 year low of $0.86 and a 1 year high of $6.00. The company’s 50-day moving average is $1.20 and its 200-day moving average is $1.96. The stock has a market capitalization of $24.37 million, a PE ratio of -0.63 and a beta of -1.78.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Empower Advisory Group LLC bought a new stake in shares of Tempest Therapeutics during the 3rd quarter worth $49,000. Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics during the second quarter worth about $55,000. Fullcircle Wealth LLC bought a new stake in Tempest Therapeutics in the third quarter worth about $87,000. Finally, Virtu Financial LLC raised its position in Tempest Therapeutics by 69.2% in the first quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after acquiring an additional 11,689 shares during the period. Institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.